Man Group’s Tenaya Therapeutics TNYA Stock Holding History

Man Group’s Portfolio TNYA Stock Details TNYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-38,540	Closed	-$125K	–	2281
2023 Q4	$125K	Buy	+38,540	New	+$83.2K	﹤0.01%	1963
2023 Q3	–	Hold	0	–	–	–	1837
2023 Q1	–	Hold	0	–	–	–	1940

Other funds holding TNYA

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Man Group's TNYA Position: Q1 2024 in Review

Man Group sold out of Tenaya Therapeutics (TNYA) in Q1 2024, closing a stake of 38,540 shares — an estimated $125K sold.

Man Group first reported a position in TNYA in Q4 2023 and held it in 1 quarter. The position peaked at $125K in Q4 2023. 90 funds tracked by Wall St. Rank hold TNYA as of Q1 2024.

Man Group reported no remaining Tenaya Therapeutics position as of Q1 2024 after selling out during the quarter.
Man Group sold 38,540 Tenaya Therapeutics shares in Q1 2024, an estimated $125K.
Man Group first reported a position in Tenaya Therapeutics in Q4 2023 and held it in 1 quarter.
Man Group's Tenaya Therapeutics position peaked at $125K in Q4 2023.
90 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q1 2024.

Based on Man Group's 13F filing for Q1 2024, filed 15 May 2024.